Other Infectious and Parasitic Diseases DRG Reimbursement

Acute antimicrobial optimization trials: randomized or pragmatic studies evaluating rapid diagnostic-guided antimicrobial selection and de-escalation strategies for hospitalized adults with diverse non-MCC infectious and parasitic diagnoses (for example bacteremia without organ failure, uncomplicated severe cellulitis, or parasitic enteritis). These studies enroll patients at admission or early inpatient stay to test whether rapid diagnostics and protocolized stewardship reduce antibiotic exposure, length of stay, and adverse events while maintaining clinical cure. Findings are directly relevant to hospital clinicians and payers because improved antimicrobial targeting can reduce inpatient resource use, drug costs, and readmissions for this heterogeneous DRG group.
Comparative effectiveness studies of site-of-care and procedural management: observational cohorts or randomized trials comparing inpatient versus accelerated outpatient management pathways (including short-stay observation units, outpatient parenteral antimicrobial therapy, or early source-control procedures) for specific infections categorized in this DRG. These trials focus on subpopulations such as older adults with limited comorbidity burden, patients with localized abscesses, or parasitic infections requiring brief inpatient therapy, assessing outcomes like complications, rehospitalization, and total cost of care. For providers and payers, this research informs safe opportunities to shift care out of acute inpatient settings, optimizing reimbursement, bed utilization, and patient-centered outcomes.
Post-discharge outcomes and health services research: longitudinal studies tracking functional recovery, infection recurrence, antibiotic-related adverse events, and healthcare utilization after hospitalization for other infectious/parasitic diagnoses without CC/MCC. These studies examine predictors of readmission, adherence to follow-up, and social determinants that influence recovery in a diverse population often discharged quickly but at risk for relapse or complications. Payers and care managers use this evidence to design targeted transitional care interventions, case management, and reimbursement models that reduce avoidable readmissions and downstream costs for this DRG cohort.

Acute antimicrobial optimization trials: randomized or pragmatic studies evaluating rapid diagnostic-guided antimicrobial selection and de-escalation strategies for hospitalized adults with diverse non-MCC infectious and parasitic diagnoses (for example bacteremia without organ failure, uncomplicated severe cellulitis, or parasitic enteritis). These studies enroll patients at admission or early inpatient stay to test whether rapid diagnostics and protocolized stewardship reduce antibiotic exposure, length of stay, and adverse events while maintaining clinical cure. Findings are directly relevant to hospital clinicians and payers because improved antimicrobial targeting can reduce inpatient resource use, drug costs, and readmissions for this heterogeneous DRG group.
Comparative effectiveness studies of site-of-care and procedural management: observational cohorts or randomized trials comparing inpatient versus accelerated outpatient management pathways (including short-stay observation units, outpatient parenteral antimicrobial therapy, or early source-control procedures) for specific infections categorized in this DRG. These trials focus on subpopulations such as older adults with limited comorbidity burden, patients with localized abscesses, or parasitic infections requiring brief inpatient therapy, assessing outcomes like complications, rehospitalization, and total cost of care. For providers and payers, this research informs safe opportunities to shift care out of acute inpatient settings, optimizing reimbursement, bed utilization, and patient-centered outcomes.
Post-discharge outcomes and health services research: longitudinal studies tracking functional recovery, infection recurrence, antibiotic-related adverse events, and healthcare utilization after hospitalization for other infectious/parasitic diagnoses without CC/MCC. These studies examine predictors of readmission, adherence to follow-up, and social determinants that influence recovery in a diverse population often discharged quickly but at risk for relapse or complications. Payers and care managers use this evidence to design targeted transitional care interventions, case management, and reimbursement models that reduce avoidable readmissions and downstream costs for this DRG cohort.

OpenPayer

Summary & Overview

Other Infectious and Parasitic Diseases Diagnoses without CC/MCC: Inpatient Reimbursement Overview

DRG 869 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes